文献速递淋巴瘤造血干细胞移植与细胞治疗

抗PD-L1抗体启动时机影响CD19 CAR T细胞治疗大B细胞淋巴瘤的疗效与毒性

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

这项1期临床试验(NCT02706405)将自体CD19 CAR T细胞(JCAR014)与递增剂量的抗PD-L1单抗度伐利尤单抗联合用于成人大B细胞淋巴瘤,度伐利尤单抗在CAR T细胞输注前或后启动。度伐利尤单抗联合JCAR014安全且未增加自身免疫或免疫效应细胞相关毒性;CAR T输注前启动度伐利尤单抗者细胞因子释放综合征发生更晚、持续时间更短但疗效更差;CAR T后持续度伐利尤单抗与CAR T细胞再扩增、CD19阳性和CD19阴性肿瘤晚期消退及缓解持续时间延长相关。

要点

  • 度伐利尤单抗联合JCAR014安全,未增加自身免疫或免疫效应细胞相关毒性。
  • CAR T输注前启动度伐利尤单抗者细胞因子释放综合征发生更晚、持续时间更短,但疗效更差。
  • CAR T后持续度伐利尤单抗与CAR T细胞再扩增、肿瘤晚期消退及缓解持续时间延长相关。

核心结论

  • PD-L1阻断的启动时机是影响成人LBCL患者CD19 CAR T细胞免疫治疗结局的关键变量。

研究设计与样本

  • 1期临床试验(NCT02706405),成人LBCL患者接受自体CD19 CAR T细胞(JCAR014)联合递增剂量抗PD-L1单克隆抗体度伐利尤单抗,度伐利尤单抗在CAR T细胞输注前或后启动。

主要发现

  • 度伐利尤单抗联合JCAR014安全,未增加自身免疫或免疫效应细胞相关毒性。
  • CAR T输注前启动度伐利尤单抗者细胞因子释放综合征发生更晚、持续时间更短,且疗效更差,与CAR T细胞积累更慢及血中炎症细胞因子浓度更低相关。
  • CAR T输注前启动度伐利尤单抗导致可溶性PD-L1(sPD-L1)水平早期升高,与血中CAR T细胞最大积累时间重合。
  • 体外实验中sPD-L1呈剂量依赖性抑制CAR T细胞效应功能,可能 contribute 于CAR T前接受度伐利尤单抗患者观察到的较差疗效。
  • 尽管疗效未改善且输注后早期CAR T细胞动力学相似,CAR T后持续度伐利尤单抗治疗与血中CAR T细胞再扩增、CD19阳性和CD19阴性肿瘤晚期消退及缓解持续时间延长相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More than half of the patients treated with CD19-targeted chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL) do not achieve durable remission, which may be partly due to PD-1/PD-L1-associated CAR T-cell dysfunction. We report data from a phase 1 clinical trial (NCT02706405), in which adults with LBCL were treated with autologous CD19 CAR T cells (JCAR014) combined with escalating doses of the anti-PD-L1 monoclonal antibody, durvalumab, starting either before or after CAR T-cell infusion. The addition of durvalumab to JCAR014 was safe and not associated with increased autoimmune or immune effector cell-associated toxicities. Patients who started durvalumab before JCAR014 infusion had later onset and shorter duration of cytokine release syndrome and inferior efficacy, which was associated with slower accumulation of CAR T cells and lower concentrations of inflammatory cytokines in the blood. Initiation of durvalumab before JCAR014 infusion resulted in an early increase in soluble PD-L1 (sPD-L1) levels that coincided with the timing of maximal CAR T-cell accumulation in the blood. In vitro, sPD-L1 induced dose-dependent suppression of CAR T-cell effector function, which could contribute to inferior efficacy observed in patients who received durvalumab before JCAR014. Despite the lack of efficacy improvement and similar CAR T-cell kinetics early after infusion, ongoing durvalumab therapy after JCAR014 was associated with re-expansion of CAR T cells in the blood, late regression of CD19+ and CD19- tumors, and enhanced duration of response. Our results indicate that the timing of initiation of PD-L1 blockade is a key variable that affects outcomes after CD19 CAR T-cell immunotherapy for adults with LBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hirayama AV, Kimble EL, Wright JH, et al. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024. PMID: 37903325. doi:10.1182/bloodadvances.2023011287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。